James Sprigler

James Sprigler serves as the primary contracting professional within the CDC Office of Acquisition Services, responsible for managing complex procurement actions that enable critical public health infrastructure. He oversees the acquisition of pharmaceutical preparations, diagnostic systems, and biomedical research capabilities essential to the CDC’s mission of disease surveillance, laboratory modernization, and rapid response to emerging health threats. His portfolio centers on high-stakes, science-driven procurements that support national readiness, including the procurement of clinical diagnostics, vaccine development materials, and advanced laboratory equipment. Sprigler ensures compliance with federal acquisition regulations while aligning contracting strategies with the CDC’s scientific and operational priorities. He maintains longstanding relationships with key industry partners including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, Cepheid, and the New York City Health & Hospitals Corp. These partnerships reflect a focus on established, high-capacity vendors capable of delivering complex biomedical solutions under stringent regulatory and quality control standards. Sprigler’s contracting approach emphasizes technical rigor, supply chain reliability, and adherence to biosafety and Good Manufacturing Practices, often involving multi-year, performance-based agreements for mission-critical products and services. Sprigler’s procurement activity is entirely non-set-aside, with 100% of awards awarded under full and open competition. This reflects a strategic emphasis on accessing the broadest possible pool of technical expertise and manufacturing capacity, prioritizing capability and compliance over socioeconomic set-asides. While small business participation is not formally targeted through set-asides, his contracting actions remain compliant with all federal small business goals through subcontracting opportunities and vendor diversity within awarded contracts. His primary NAICS focus is 325412 (Pharmaceutical Preparation Manufacturing), underscoring deep expertise in procuring active pharmaceutical ingredients, diagnostic reagents, and standardized biological materials. He specializes in acquisitions involving GMP-compliant production, cold chain logistics, and FDA-regulated products, ensuring the CDC’s access to safe, effective, and scalable medical countermeasures for national health emergencies.